What is HC Wainwright's Forecast for MNPR FY2029 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Research analysts at HC Wainwright reduced their FY2029 earnings estimates for shares of Monopar Therapeutics in a research note issued to investors on Tuesday, April 1st. HC Wainwright analyst S. Lee now expects that the company will earn $3.35 per share for the year, down from their previous forecast of $3.66. HC Wainwright has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($1.87).

Several other research analysts have also recently issued reports on the stock. Jones Trading reissued a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday. Piper Sandler restated an "overweight" rating and issued a $76.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $44.00.

Remove Ads

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock traded down $4.59 during mid-day trading on Wednesday, reaching $30.00. 42,416 shares of the company were exchanged, compared to its average volume of 360,003. Monopar Therapeutics has a twelve month low of $1.72 and a twelve month high of $54.30. The firm's 50-day simple moving average is $38.29 and its two-hundred day simple moving average is $25.03. The firm has a market cap of $183.39 million, a PE ratio of -15.23 and a beta of 1.01.

Institutional Investors Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics during the fourth quarter worth about $45,000. Geode Capital Management LLC raised its position in shares of Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after purchasing an additional 24,530 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Monopar Therapeutics during the 4th quarter worth approximately $2,861,000. Point72 Asset Management L.P. purchased a new stake in Monopar Therapeutics in the 4th quarter valued at approximately $3,694,000. Finally, RA Capital Management L.P. acquired a new stake in Monopar Therapeutics during the 4th quarter valued at $11,247,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the sale, the insider now directly owns 822,255 shares in the company, valued at approximately $28,778,925. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 34.90% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.